Tenax Therapeutics Q1 EPS $(3.12) Misses $(2.40) Estimate
Portfolio Pulse from Benzinga Newsdesk
Tenax Therapeutics reported Q1 EPS losses of $(3.12), missing the consensus estimate of $(2.40) by 30%. This represents a 74% decrease in losses compared to $(12.00) per share from the same period last year.
May 14, 2024 | 12:25 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Tenax Therapeutics missed Q1 EPS estimates, reporting losses of $(3.12) per share compared to the expected $(2.40). Despite this miss, the company has significantly reduced its losses compared to the previous year.
Missing the EPS estimate by 30% is likely to negatively impact investor sentiment in the short term, leading to a potential decrease in TENX stock price. However, the significant reduction in losses year-over-year may provide some offsetting positive sentiment.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100